Phase 1 Evaluation of [18F]MK-6240 PET as an Imaging Marker for Tau Protein

Completed · Early Phase 1

Conditions studied: Alzheimer Disease, Healthy Volunteers

In brief

The overall goal of this protocol is to evaluate \[18F\]MK-6240 (also known as \[18F\]MNI-946) a tau targeted radiopharmaceutical.

Key facts

Study ID

NCT03071224

Run by

Invicro

People needed

10

Starts

2016-06-01

Expected to finish

2021-06-09

Last updated by the study team

2021-06-14

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: accepted.

Where it is running

• Invicro — New Haven, Connecticut, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.